Stockscreener 앱 받기
6.18
5.28%
0.31
Minerva Neurosciences Inc 주식(NERV)의 최신 뉴스
NERV Initiates Coverage On Citizens -- Rating Set to Market Outp - GuruFocus
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates Minerva Neurosciences stock at outperform, $14 target By Investing.com - Investing.com India
Citizens initiates Minerva Neurosciences stock at outperform, $14 target - Investing.com
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Yahoo Finance
Retail Surge: Is Minerva Neurosciences Inc stock technically oversold2026 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Minerva Neurosciences, Inc. Files Form 8-K with SEC – Company Information and Key Details (April 6, 2026) 14 - Minichart
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
Minerva Neurosciences sets June 2026 date for annual stockholder meeting By Investing.com - Investing.com Australia
Minerva Neurosciences sets June 2026 date for annual stockholder meeting - Investing.com
Minerva Neurosciences sets June 3, 2026 annual meeting; stockholder notice deadlines announced - TradingView — Track All Markets
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - Stock Titan
Ideas Watch: Is Minerva Neurosciences Inc stock a hidden gemPortfolio Gains Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail
Minerva Neurosciences names Jim O’Connor as chief business officer By Investing.com - Investing.com Canada
Minerva Announces Leadership Transition - Bitget
Minerva announces leadership transition - MarketScreener
Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO Following Leadership Transition - geneonline.com
Minerva Neurosciences names Jim O’Connor as chief business officer - Investing.com
Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins - Stock Titan
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV - MarketBeat
NERV Technical Analysis & Stock Price Forecast - Intellectia AI
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Tr - GuruFocus
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Treatment - GuruFocus
Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV) - Stock Titan
Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice - Stock Titan
NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered - Stock Titan
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - The Manila Times
Profit Recap: What is the earnings history of Minerva Neurosciences Inc2026 Bull vs Bear & Detailed Earnings Play Strategies - baoquankhu1.vn
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia - Seeking Alpha
Guidance Update: Can Minerva Neurosciences Inc stock outperform in a bear market2026 Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8% - MarketBeat
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Minerva Neurosciences : Olanzapine added to Roluperidone, in patients with negative symptoms (NS) of schizophrenia - marketscreener.com
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - Investing News Network
Minerva Neurosciences Presents Data from its Open-label - globenewswire.com
Market Overview: Can Minerva Neurosciences Inc continue delivering strong returns2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms - MarketBeat
[EFFECT] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Minerva Neurosciences, IncCommon Stock (NQ: NERV - markets.chroniclejournal.com
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV) - The Globe and Mail
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
2.69%
0.25%
자본화:
|
볼륨(24시간):